|
FRMD4B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.05569999964139E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.02059999999671E-05 |
| Normal-vs-Stage2 |
3.916100E-02 |
| Normal-vs-Stage3 |
1.93870000053664E-08 |
| Normal-vs-Stage4 |
2.98160000022918E-08 |
| Stage1-vs-Stage2 |
6.511600E-01 |
| Stage1-vs-Stage3 |
1.813950E-02 |
| Stage1-vs-Stage4 |
1.014030E-02 |
| Stage2-vs-Stage3 |
1.075240E-01 |
| Stage2-vs-Stage4 |
5.322200E-02 |
| Stage3-vs-Stage4 |
4.958800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.8292000025788E-08 |
| Normal-vs-AfricanAmerican |
3.668500E-02 |
| Normal-vs-Asian |
8.566100E-02 |
| Caucasian-vs-AfricanAmerican |
3.637600E-01 |
| Caucasian-vs-Asian |
3.467700E-02 |
| AfricanAmerican-vs-Asian |
5.855600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.46479999996174E-06 |
| Normal-vs-Female |
3.05509999964926E-07 |
| Male-vs-Female |
7.495000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.02830000000698E-05 |
| Normal-vs-Age(41-60Yrs) |
3.00650000006897E-07 |
| Normal-vs-Age(61-80Yrs) |
1.9800999995212E-07 |
| Normal-vs-Age(81-100Yrs) |
6.435600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.346000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.254030E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.250800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.142800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.704400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.930600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.26690000046281E-07 |
| Classical-VS-Follicular |
4.883300E-03 |
| Classical-VS-Other |
7.787800E-01 |
| Classical-VS-Normal |
1.49590000053657E-07 |
| Tall-VS-Follicular |
1.03359999448216E-08 |
| Tall-VS-Other |
1.314630E-01 |
| Tall-VS-Normal |
7.32747196252603E-15 |
| Follicular-VS-Other |
2.779800E-01 |
| Follicular-VS-Normal |
2.591200E-01 |
| Other-VS-Normal |
1.081750E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.370290E-04 |
| Normal-vs-N1 |
1.002680E-04 |
| N0-vs-N1 |
2.628200E-01 |
|
|
